The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The risk of subsequent malignancies after CD19 CAR-T for B-cell lymphoma: a retrospective analysis
Parastoo Dahi, MD, MS, Memorial Sloan Kettering, New York City, NY, comments on the risk of subsequent malignancies after CD19 CAR T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma, outlining the findings from a retrospective analysis of 355 patients. Dr Dahi notes that the benefits of CAR T-cell therapy continue to outweigh the risks, but that patients should be monitored lifelong to detect any potential subsequent malignancies early. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The risk of subsequent malignancy has recently emerged after the addition of the FDA black box warning for CAR-T products, which resulted from the cases of T-cell lymphomas that were seen after the CAR T-cell therapy. And in some of those cases, the CAR transgene was identified in the malignant cells, suggesting that there is a potential link.
We retrospectively looked at 355 patients with relapsed/refractory B-cell lymphomas that had received CD19-targeted CAR T-cell products between 2016 and 2022...
The risk of subsequent malignancy has recently emerged after the addition of the FDA black box warning for CAR-T products, which resulted from the cases of T-cell lymphomas that were seen after the CAR T-cell therapy. And in some of those cases, the CAR transgene was identified in the malignant cells, suggesting that there is a potential link.
We retrospectively looked at 355 patients with relapsed/refractory B-cell lymphomas that had received CD19-targeted CAR T-cell products between 2016 and 2022. And in this retrospective study, the cumulative incidence of subsequent malignancies at 36 months was 6% for solid tumors, and 4.5% for hematologic malignancies, which is relatively similar to the rate that is observed with other cancer treatments. We didn’t observe any cases of T-cell malignancies, and the only significant factor associated with subsequent malignancy was older age, basically. And most of the non-relapse deaths in our report were due to infection.
So, the overall CAR-T therapy seems to be relatively low risk for, you know, I mean, relatively low or similar risk for potentially subsequent malignancies as other cancer treatments. So, you know, the benefits of CAR T-cells continue to outweigh their risks. Because there is this potential risk of CAR T-cells, actually, nowadays, we should follow up patients and screen them for subsequent malignancies lifelong, basically.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
